このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Aligos Therapeutics 将来の成長

Future 基準チェック /26

Aligos Therapeuticsは、6.6%と80.4%でそれぞれ年率6.6%で利益と収益が成長すると予測される一方、EPSはgrowで15.8%年率。

主要情報

6.6%

収益成長率

15.8%

EPS成長率

Biotechs 収益成長	24.1%
収益成長率	80.4%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	06 Jun 2024

今後の成長に関する最新情報

Recent updates

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues

May 24

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Apr 09

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues

Feb 23

Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Oct 24

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Jul 17

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Mar 11

Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B

Jul 25

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Jul 11

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Feb 02

Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Oct 19

Aligos Therapeutics EPS beats by $0.16

May 10

We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely

May 01

What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?

Jan 16

Dosing underway for Aligos Therapeutics' hepatitis B candidate in early-stage study

Oct 30

業績と収益の成長予測

NasdaqCM:ALGS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-145	N/A	N/A	1
12/31/2025	N/A	-120	N/A	N/A	1
12/31/2024	1	-114	N/A	N/A	1
3/31/2024	14	-100	-79	-79	N/A
12/31/2023	16	-88	-79	-79	N/A
9/30/2023	16	-82	-73	-73	N/A
6/30/2023	17	-82	-70	-70	N/A
3/31/2023	14	-83	-82	-81	N/A
12/31/2022	14	-96	-80	-79	N/A
9/30/2022	11	-112	-101	-100	N/A
6/30/2022	8	-126	-110	-108	N/A
3/31/2022	6	-136	-107	-106	N/A
12/31/2021	4	-128	-117	-116	N/A
9/30/2021	4	-125	-98	-98	N/A
6/30/2021	2	-125	-90	-89	N/A
3/31/2021	1	-116	-85	-84	N/A
12/31/2020	N/A	-109	-76	-74	N/A
9/30/2020	N/A	-92	-72	-70	N/A
6/30/2020	N/A	-73	-69	-66	N/A
3/31/2020	N/A	-62	-61	-58	N/A
12/31/2019	N/A	-52	-50	-47	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ALGS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ALGS今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ALGS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ALGSの収益 ( 80.4% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: ALGSの収益 ( 80.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ALGSの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Aligos Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased to US$2.84

Price target decreased to US$2.55

Consensus revenue estimates increase by 43%

Consensus revenue estimates increase by 202%

Price target decreased to US$6.10

Price target decreased to US$12.25

Recent updates

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2A Herald Study for the Treatment of Mash

First quarter 2024 earnings released: US$0.22 loss per share (vs US$0.54 loss in 1Q 2023)

Aligos Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

Aligos Therapeutics, Inc. Announces the Initiation of the Phase 2a HERald Study of ALG-055009 in MASH Subjects

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Aligos Therapeutics, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues

Aligos Therapeutics, Inc. Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)

Aligos Therapeutics, Inc. Announces Executive Changes

Aligos Therapeutics, Inc. Presents Clinical and Nonclinical Data at the AASLD Liver Meeting®? 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Aligos Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New major risk - Shareholder dilution

Aligos Therapeutics, Inc. announced that it has received $92.149997 million in funding from EcoR1 Capital, LLC, Deep Track Capital, LP, Armistice Capital LLC, Roche Venture Fund

Aligos Therapeutics, Inc. announced that it expects to receive $92.149997 million in funding from EcoR1 Capital, LLC, Deep Track Capital, LP, Armistice Capital LLC, Roche Venture Fund and other investors

Aligos Therapeutics, Inc. announced that it expects to receive $92.149997 million in funding from EcoR1 Capital, LLC, Deep Track Capital, LP, Armistice Capital LLC, Roche Venture Fund and other investors

Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Aligos Therapeutics Receives Non-Compliance Notice From Nasdaq

Aligos Therapeutics Receives Non-Compliance Notice From Nasdaq

Second quarter 2023 earnings released: US$0.43 loss per share (vs US$0.47 loss in 2Q 2022)

Aligos Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

New major risk - Revenue and earnings growth

Aligos Therapeutics Presents Data from Its Liver Disease Programs At the European Association for the Study of the Liver (Easl) Congress 2023

First quarter 2023 earnings released: US$0.54 loss per share (vs US$0.84 loss in 1Q 2022)

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target increased to US$2.84

Aligos Therapeutics, Inc. on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009

Price target decreased to US$2.55

Consensus revenue estimates increase by 43%

Aligos Therapeutics Presents Clinical Data for Its Capsid Assembly Modulator, Alg-000184, At Aasld’S the Liver Meeting® 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aligos Therapeutics, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Aligos Therapeutics Initiates Dosing in Healthy Volunteers with siRNA Drug Candidate ALG-125755

Aligos Therapeutics, Inc. Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud

Consensus revenue estimates increase by 202%

Second quarter 2022 earnings released: US$0.47 loss per share (vs US$0.79 loss in 2Q 2021)

Aligos Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Aligos Therapeutics, Inc. Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating its Class II Capsid Assembly Modulator, ALG-000184

Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Aligos Therapeutics, Inc.(NasdaqGS:ALGS) dropped from Russell 2000 Growth Index

Aligos Therapeutics, Inc. to Participate in Metropolitan Antiviral Drug Accelerator, Recipient of NIH and NIAID Grant to Develop Therapeutics Against Coronaviruses and Pathogens of Pandemic Potential

First quarter 2022 earnings released: US$0.84 loss per share (vs US$0.74 loss in 1Q 2021)

Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs

Aligos Therapeutics, Inc., Annual General Meeting, Jun 23, 2022

Price target decreased to US$6.10

Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development

Aligos Therapeutics, Inc. Receives Notice of A Complaint

Price target decreased to US$12.25

Aligos Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)

Price target decreased to US$19.20

Aligos Therapeutics, Inc. Halting Further Development of STOPS™ Drug Candidate, ALG-010133

Price target decreased to US$30.80

Aligos Therapeutics Begins Dosing with NASH Drug Candidate, ALG-055009, in Healthy Volunteers in A Phase 1 First-In-Human Study

Aligos Presents Update of Chronic Hepatitis B Pipeline Portfolio at HEP DART 2021

Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Consensus revenue estimates increase to US$2.47m

Aligos Therapeutics, Inc.(NasdaqGS:ALGS) dropped from Russell Microcap Value Index

Aligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects